Forward Pharma A/S, a biopharmaceutical company, focuses on the provision of dimethyl fumarate (DMF) formulations for the treatment of various immune disorders. It develops FP187, a DMF formulation to treat relapsing remitting multiple sclerosis and psoriasis. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.
